Browse the evidence

Endurance exercise training increases the proportion of slow-twitch (ST) fibers and oxidative capacity, which protects against insulin resistance and obesity.

Incorporate regular endurance exercise into your routine. This type of training triggers molecular changes (increasing PGC-1 and PPAR-α) that shift your muscle toward a more metabolically efficient, insulin-sensitive state, helping to prevent obesity and type 2 diabetes.

Discontinuation of GLP-1 agonist pharmacotherapy (e.g., semaglutide) leads to rapid weight regain, necessitating indefinite long-term treatment for maintenance.

If you use GLP-1 medications like semaglutide for weight loss, understand that stopping them will likely cause you to regain the weight quickly. These drugs treat obesity as a chronic condition, meaning you likely need to stay on them long-term to keep the weight off, regardless of cost or insurance hurdles.

Newer GLP-1 and dual-agonist obesity medications produce significant weight loss (15-21%) and metabolic benefits, but discontinuation leads to weight regain.

Use GLP-1 medications as a long-term tool for weight management, not a short-term fix. Be prepared to continue treatment to maintain weight loss, as stopping often leads to regain.

GLP-1 analogs (e.g., Semaglutide, Liraglutide) and dual agonists (Tirzepatide) produce significant weight loss (up to 21%) but are associated with high costs, lifelong administration requirements, and gastrointestinal side effects that may drive patients toward complementary therapies.

GLP-1 drugs (Semaglutide, Tirzepatide) are highly effective for weight loss (15-21%), but they are expensive, require lifelong injections, and cause GI side effects. If you experience side effects or cannot afford long-term use, you are not alone; many patients seek complementary therapies like TCM to manage weight and side effects.

In patients with advanced chronic liver disease (ACLD), achieving >10% body weight loss through therapeutic lifestyle interventions significantly reduces portal hypertension and improves survival, although this magnitude of weight loss is difficult to sustain long-term.

For ACLD patients, aiming for >10% weight loss via diet and exercise can significantly lower portal pressure and improve survival. However, this is hard to maintain; consider medical weight loss aids if lifestyle changes alone fail to sustain the loss.

New generation obesity medications (GLP-1/GIP agonists) achieve mean weight loss of 15–25% over 68–72 weeks, narrowing the efficacy gap between medical and surgical management of obesity.

New GLP-1/GIP medications like semaglutide (2.4mg weekly) and tirzepatide are highly effective, producing 15-25% weight loss over ~1.5 years. This efficacy is now comparable to surgery, making medication a primary, not just secondary, option for obesity treatment.

High body mass index (BMI) and visceral adiposity are strong independent risk factors for the development and progression of chronic kidney disease (CKD), end-stage renal disease (ESRD), and obesity-related glomerulopathy (ORG).

Maintaining a healthy weight is one of the most effective ways to protect your kidneys. High body weight puts direct mechanical and hormonal stress on your kidneys, increasing the risk of kidney failure. If you are overweight, even modest weight loss through diet and exercise can significantly lower your risk of developing kidney disease or slow its progression.

Poor glycemic control exacerbates dyslipidemia in diabetes by increasing hepatic VLDL production and decreasing HDL levels, while improvements in glycemic control can reverse these lipid abnormalities.

For people with diabetes, keeping blood sugar levels in range is important, but it is not enough to protect your heart. Even if your A1C is good, you likely still have abnormal cholesterol levels, specifically high triglycerides and low HDL. This is because diabetes changes how your liver processes fats. You need to monitor your lipid profile separately and likely take medication (like statins) to manage cardiovascular risk, regardless of how well your blood sugar is controlled.

A Body Shape Index (ABSI) is associated with incident cardiovascular disease, with the highest risk observed in individuals with high ABSI combined with high RCII.

For adults over 45, monitoring your Body Shape Index (ABSI) alongside your cholesterol and inflammation levels (RCII) provides a more accurate assessment of heart disease risk than weight alone. If you have a high ABSI and high RCII, you are in a high-risk subgroup that may benefit from intensified lifestyle interventions.

Ultra rapid lispro (URLi) administered as a bolus with basal insulin improves postprandial glucose excursions (PPGE) after breakfast more effectively than standard insulin lispro in adults with type 2 diabetes, while maintaining non-inferior HbA1c reduction and similar safety profiles regarding hypoglycemia and weight gain.

If you have Type 2 Diabetes and struggle with high blood sugar after meals, especially breakfast, ask your doctor about Ultra Rapid Lispro (URLi). It is taken exactly like your current rapid-acting insulin (just before eating) but absorbs faster to better match your food. This can significantly reduce the sharp blood sugar spikes after breakfast without increasing your risk of low blood sugar or weight gain compared to standard insulin lispro.

High consumption of long-chain omega-3 fatty acids is associated with a significantly lower risk of developing laparoscopically confirmed endometriosis.

Focus on increasing intake of long-chain omega-3 fatty acids, primarily found in fatty fish (like tuna and dark fish) and certain salad dressings, as higher consumption is linked to a lower risk of endometriosis in large prospective studies. This does not mean avoiding all fats, as total fat intake showed no association, but rather prioritizing specific beneficial fatty acids.

Metformin is the preferred initial oral hypoglycemic monotherapy for type 2 diabetes due to its efficacy, safety, and low risk of hypoglycemia and weight gain.

Start with metformin as your first medication if lifestyle changes alone aren't enough. It is the standard because it works well, is safe long-term, and rarely causes low blood sugar or weight gain. If your blood sugar isn't controlled, your doctor will add another medication.

If metformin is contraindicated or not tolerated, other oral hypoglycemic agents (DPP4 inhibitors, SGLT2 inhibitors, Sulfonylureas, etc.) can be used as initial monotherapy based on clinical situation.

If you can't take metformin, your doctor will choose another medication based on your specific health needs, such as kidney function or heart risk. Options include DPP4 inhibitors, SGLT2 inhibitors, or others.

Among pharmacotherapies, Semaglutide 2.4 mg and Orlistat have the most favorable safety/tolerability profiles, while Liraglutide 3.0 mg has the least tolerability, and Tirzepatide has intermediate tolerability.

When choosing a weight loss medication, be aware that tolerability varies. Semaglutide and Orlistat tend to be better tolerated, while Liraglutide may cause more side effects. Tirzepatide, despite its high efficacy, has intermediate tolerability, meaning you might experience more side effects than with Semaglutide or Orlistat.

Combining the amylin analog pramlintide with the leptin analog metreleptin produces significantly greater weight loss in obese humans than either agent alone, primarily by synergistically enhancing fat loss and mitigating metabolic counter-regulation.

For obese or overweight individuals without diabetes, combining pramlintide and metreleptin offers significantly better weight loss than using either drug alone. The regimen involves twice-daily subcutaneous injections taken before meals, alongside a moderate caloric deficit. While side effects like nausea and injection site reactions occur, they tend to be mild and diminish over time. This approach is particularly useful for those who experience weight loss plateaus with standard therapies.

Improvements in insulin sensitivity (HOMA-IR) and intrahepatic lipid content during caloric restriction are transient and not maintained during the weight maintenance phase, unlike other cardiometabolic markers.

Be aware that while caloric restriction improves insulin sensitivity during the weight loss phase, this specific benefit may not persist once you stop losing weight, even if you maintain the lower calorie intake. Other cardiovascular benefits, like lower blood pressure and better cholesterol, do persist. This suggests that maintaining a healthy weight and diet is crucial, but you might need additional strategies (like exercise or specific dietary components) to sustain insulin sensitivity improvements long-term.

Performing resistance training in an energy deficit impairs lean mass gains compared to training in energy balance, but does not impair strength gains.

If you are trying to lose weight while lifting weights, expect to get stronger but not necessarily bigger. A 500 kcal daily deficit will likely stop you from gaining lean mass, but you will still improve your strength. To maximize muscle growth, you must avoid prolonged energy deficits.

Meal replacements improve satiety and reduce cravings during caloric restriction through mechanisms like stimulus narrowing and ketosis, despite expected hormonal changes.

You might worry that eating less will make you hungry, but using meal replacements can actually help control hunger. By limiting food choices (stimulus narrowing) and potentially inducing ketosis, MRs can reduce cravings and make sticking to a diet easier.

Continued treatment with Tirzepatide maintains significant weight loss and cardiometabolic improvements, whereas discontinuation leads to partial weight regain and loss of benefits, demonstrating that long-term adherence is required to sustain outcomes.

If you are using Tirzepatide for weight loss, understand that it is a long-term treatment, not a short-term fix. Stopping the medication will likely cause you to regain most of the weight you lost. To keep the weight off, you must continue the medication indefinitely, combined with healthy lifestyle habits, just as you would manage high blood pressure with medication.

Sleep duration has a U-shaped association with weight gain, with greater weight gain occurring with less than 6 hours or more than 8 hours of sleep per night.

Aim for 6-7 hours of sleep per night. Both less than 6 hours and more than 8 hours are associated with greater weight gain. Prioritize consistent, adequate sleep for weight management.

Supplementation with omega-3 fatty acids (EPA and DHA) reduces systemic inflammation and clinical symptoms in autoimmune and inflammatory diseases by suppressing proinflammatory cytokines (IL-1, TNF, IL-6) and shifting eicosanoid production toward less inflammatory derivatives.

If you have an inflammatory or autoimmune condition, increasing your intake of EPA and DHA (found in fish oil) may help reduce inflammation and symptoms. This is achieved by suppressing proinflammatory cytokines like IL-1 and TNF. While dietary changes are beneficial, therapeutic doses often require supplementation to achieve sufficient levels in cell membranes.

A high omega-6 to omega-3 fatty acid ratio in the diet contributes to increased incidence of cardiovascular disease and inflammatory disorders by promoting the production of proinflammatory eicosanoids and cytokines.

To reduce inflammation and cardiovascular risk, aim to balance your intake of omega-6 and omega-3 fatty acids. This involves reducing excessive omega-6 intake (common in Western diets) and increasing omega-3 intake, potentially through diet or supplementation.

High dietary glycemic load combined with low cereal fiber intake significantly increases the risk of non-insulin-dependent diabetes mellitus (NIDDM) in men, independent of other known risk factors.

To lower your risk of type 2 diabetes, focus on the quality of your carbohydrates rather than just cutting them out. Choose minimally refined grains (high cereal fiber) and avoid foods that spike blood sugar rapidly (high glycemic load). Combining high-fiber, low-glycemic foods is the most protective dietary strategy identified.

Higher dietary glycemic index is positively associated with an increased risk of NIDDM in men, but this association is statistically significant only after adjusting for cereal fiber intake.

Monitor the Glycemic Index of your carbohydrate sources. While total carbs matter, the speed at which they enter your bloodstream (Glycemic Index) impacts diabetes risk. Prioritize low-GI foods to manage insulin demand.